Maraviroc
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Maraviroc |
| DrugBank ID | DB04835 |
| Brand Names (EU) | Celsentri |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.82% |
Approved Indication (EMA)
Celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | multiple endocrine neoplasia | 99.82% | DL |
| 2 | acne (disease) | 99.76% | DL |
| 3 | primary cutaneous T-cell lymphoma | 99.72% | DL |
| 4 | pediatric systemic lupus erythematosus | 99.71% | DL |
| 5 | primary cutaneous T-cell non-Hodgkin lymphoma | 99.50% | DL |
| 6 | primary cutaneous B-cell lymphoma | 99.38% | DL |
| 7 | candidiasis | 99.28% | DL |
| 8 | complement component 4a deficiency | 99.24% | DL |
| 9 | cytomegalovirus infection | 99.23% | DL |
| 10 | HER2 positive breast carcinoma | 99.22% | DL |
| 11 | hereditary neuroendocrine tumor of small intestine | 99.16% | DL |
| 12 | psoriasis | 99.09% | DL |
| 13 | Sezary syndrome | 99.02% | DL |
| 14 | infectious bovine rhinotracheitis | 99.01% | DL |
| 15 | malignant catarrh | 99.01% | DL |
| 16 | nephrotic syndrome | 99.01% | DL |
| 17 | Ewing sarcoma | 98.95% | DL |
| 18 | eye disease | 98.91% | DL |
| 19 | amenorrhea (disease) | 98.90% | DL |
| 20 | gestational trophoblastic neoplasm | 98.88% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.